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Abstract
Background: Osteonecrosis (ON) is known to be one of the most disabling complications follow-
ing corticosteroid (CS) medications. However, evidence regarding risk of asymptomatic prevalence
of ON among different diseases and the impact of variable steroid regimens are conflicting. We
aimed to determine the prevalence of ON of femoral head in asymptomatic patients with systemic
rheumatic diseases who received high-dose CS and also clarify its relationship with different dosages
and regimens.
Methods: In this cross-sectional study, 50 consecutive patients receiving high-dose CS for rheu-
matic diseases who have no pelvic pain were recruited. MRI of both hips was performed on all pa-
tients using a 1.5 Tesla to diagnose ON.
Results: Of 50 subjects, 18 (36%) developed ON of the femoral head. Groups with and without ON
were comparable in terms of sex, age and mean starting CS dose. There was no statistical difference
in the type of CS regimen including daily dose, peak dose and cumulative dose between the two
groups. However, silent ON was associated with both the cumulative CS dose and the duration of CS
therapy.
Conclusion: According to high prevalence of ON in our selected patients with no other identifiable
risk factor for ON, monitoring of high risk patients with periodic hip MRI would help diagnose ne-
crosis in early stage.
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Introduction
Osteonecrosis is a condition characterized
by bone marrow ischemia and cell death
which may subsequently lead to insuffi-
ciency fracture and secondary osteoarthritis
requiring palliative surgery (1,2).
Although ON of the femoral head can be
caused by various conditions such as trau-
ma, alcohol abuse and hemoglobinopathies,
CS is the most common cause of non-
traumatic ON (3). At early stage, the pa-
tient may be asymptomatic but eventually
pain and limitation of movements may de-
velop.
The precise impact of the different regi-
mens of CS on ON remains a matter of de-
bate in the literature. Some studies have
claimed that ON is independent from the
peak, daily and cumulative doses of CS;
while others have reported that the appear-
ance of ON is associated with maximum
daily dose of CS (4). This cross-sectional
study was conducted to extend our
knowledge about prevalence of silent ON
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among patients taking CS and its associa-
tion with different CS regimens and dosag-
es.
Methods
Data
The patients were recruited from rheuma-
tology clinic of a major referral teaching
hospital in Tehran, Iran. We consecutively
enrolled 50 rheumatology patients who re-
ceived high-dose CS for various conditions
if they had received prednisolone≥ 30mg
daily (or its equivalent) for at least 1
month. We excluded those with any pain or
limitation of motion of hips or if  there
were any history of hip trauma, chronic al-
cohol abuse, smoking, diabetes mellitus,
hyperlipidemia, hyperuricemia, anti-
phospholipid syndrome, hyperhomocyste-
inemia, presence of V Leiden factor, and
deficiency of protein C, protein S or an-
tithromobin III factor.
The ethical aspects of the study were ap-
proved by the university review committee
and informed consent was obtained from all
of the patients prior to their participation in
the study. A structured checklist was used
to collect data on demographic variables,
dose and duration of CS therapy, and route
of CS administration. Complete blood
count, lipid panel, anti-phospholipid anti-
bodies and hypercoagulable profile were
measured in all cases. Femoral heads were
targeted for ON screening purposes as they
comprise the most frequent sites for CS-
induced ON. All MRI studies were per-
formed by a single 1.5 Tesla imaging scan-
ner and reported independently by two MRI
expert radiologists and by a third one in
case of disagreement.
ON was defined as the presence of band
of low signal intensity in classic T1 and T2-
weighted images in any portion of femoral
head. However, the radiologists were asked
to report any other abnormal signal intensi-
ties.
Statistical Analysis
Thereafter, patients were divided into the
ON and non-ON groups based on MRI
findings. Results were reported as
mean±standard deviation (SD) for the
quantitative variables and percentages for
the categorical variables. The groups were
compared using the Student's t-test for the
continuous variables and the Chi-square
test for the categorical variables. P values
of 0.05 or less were considered statistically
significant. All the statistical analyses were
performed using SPSS v. 19.0.
Results
Among 50 included patients, 32 (0.64%)
were female and 18 (0.36%) were male
with a mean±SD age of 37.3 ± 12.3 years
(range 14–65 years).
The rheumatologic diagnoses were as fol-
lows. Takayasu arteritis in 3 cases (6%),
Microscopic polyangiitis in 4 cases (8%),
Granulomatosis with polyangiitis in 5 cases
(10%), polymyositis in 10 cases (20%),
temporal arteritis in 2 cases (4%), Rheuma-
toid arthritis complicated by scleritiis in 5
cases (10%), Relapsing polychondritis in 1
cases (2%), Adult-onset Still’s disease in  3
cases (6%), Dermatomyositis in 3 cases
(6%), Systemic lupus erythematossis in 10
cases (20%), and Behçet's disease in 4 cas-
es (8%). The occurrence of ON was not
correlated with the disease of the patient
(p= 0.3).
The mean±SD duration of steroid therapy
was 4.7 ± 1.6 months (range 2–8 months)
and the mean±SD starting CS dose was
41.9 ± 9.4 mg (range 30-60 mg). Twenty
eight patients (56.0%) were administered
high cumulative dose pulse CS regimens
and others did not receive any pulse regi-
men.
We found 18 (36%) patients who suffered
from ON of femoral neck. The two groups
with and without ON were comparable in
terms of sex, age and mean starting high-
dose CS. Duration of high-dose CS con-
sumption was longer in ON patients (p=
0.0001).
Moreover, there was no significant differ-
ence in the type of steroid regimen between
the ON and non-ON groups. Total cumula-
tive CS dose was not related to ON. Alt-
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hough the cumulative high-dose was signif-
icantly higher in patients with ON than pa-
tients without ON (p= 0.0001). Among the
study population, 28 (56%) had Cushingoid
face appearance. This finding was 66% in
ON group and 50% in the other group
(p>0.05) (Table 1).
Discussion
One of the most life-threatening and disa-
bling complication following long term CS
is ON.  The risk period to develop ON is in
the first year of CS treatment, also ON is
the major cause of joint replacement among
SLE patients (5).
About 36% of patients of current study
developed ON. A study on 539 patients
with severe acute respiratory syndrome
(SARS) taking high-dose steroid reported
ON in 176 patients (32.7%) (3).
In another study on 45 SLE patients, 15
(33%) patients developed silent ON and
five patients (11%) symptomatic ON (8).
Some studies showed that occurrence of
ON was about 15% among patients with
multiple sclerosis (9).
Other study could not show any relation-
ship between total cumulative dose, pulse
or duration of steroid treatment and ON (4).
Kamata et al reported that in patients with
ON, the maximum daily dose of CS was
significantly higher (10). In review of 868
SLE patients, the high-dose of steroid dur-
ing 4 months and cumulative dose were
considerably higher in patients with ON
(11).
In another study on 540 SLE patients,
mean daily dose and intravenous pulse in
addition to cumulative dose of prednisolone
were related to ON (12).  Zhang et al
showed that the number of ON lesions was
directly associated with the dosage of CS,
pulse and cumulative regimen (13). In other
survey on 106 SLE patients during follow
up period of 13.6 years, total duration of
CS and duration of treatment was not relat-
ed to ON (14). Griffith et al showed that
cumulative CS dose is an important risk
factor for osteonecrosis. In his study, preva-
lence of ON was 0.6% for patients taking
less than 3 g and 13% for ones who receiv-
ing more (15).
In a study by Sekiya et al, ON was corre-
lated with increasing dose of CS and higher
disease activity among SLE patients (16).
A survey on 337 patients revealed that high
dose of steroid > 40 mg/day imposed a re-
markably higher risk for ON than dose<
40mg/day (17). Different study population
and ON stages (silent/symptomatic) might
be the cause of variable results in research-
es.
Our study suffers from some limitations.
All cases were recruited by one center.
Number of cases involved was not suffi-
cient to evaluate more relevant potential
variables at the same time. Baseline femo-
ral head MRI was not performed and the
exact time of ON development was unclear
in most cases.
Additionally, we were unable to calculate
the total cumulative dose of CS in 9 cases
because of insufficient data in hospital
files. We cannot rule out the bias of natural
exclusion of cases that received CS for sev-
eral years, as they had more time to become
symptomatic and lose their chance to in-
clude in our study.
We defined ON as a band of low intensity
in hip MRI. Though this definition adopted
Table 1. Baseline characteristics and clinical data in the groups with and without ON
Variable With ON (n=18) Without ON (n=32) p
Female gender 9 (50.0%) 23 (71.8%) 0.12
Age (year) 37.0 ± 9.1 37.5 ± 13.9 0.87
Duration of high dose CS use (month) 5.8 ± 1.3 4.1 ± 0.2 0.24
High-dose CS starting dose (mg)/day 44.7 ± 9.9 40.3 ± 8.9 0.36
Pulse high-dose CS regimen
Total CS cumulative dose (g)
High dose CS cumulative dose (g)
Cushingoid face appearance
11 (61.7%)
12.1±3.6
5.2 ±1.2
12 (66.6%)
17 (53.1%)
11.0 ±6.7
3.7± 1.3
16 (50.0%)
0.58
0.57
0.0001
0.11
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for its specificity, it is not highly sensitive
in early ON. We searched all MR images
for more subtle evidence of ON. No such
cases were found by study radiologists.
Conclusion
We found a relatively high rate of silent
ON in a group of patients with various
rheumatologic diseases who received high-
dose CS. The present study suggests that
MRI of hips would be appropriate for
screening of those who are at higher risk of
silent ON.
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